サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1317914

ヒトパピローマウイルスワクチン市場：適応疾患別、タイプ別、流通チャネル別-2023-2030年の世界予測

Human Papillomavirus Vaccine Market by Disease Indication, Type, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ヒトパピローマウイルスワクチン市場：適応疾患別、タイプ別、流通チャネル別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヒトパピローマウイルスワクチンの世界市場は、2023年にCAGR 7.01%で43億509万米ドルが予測され、2030年には驚異的な69億2,948万米ドルに達すると予測され、大きく成長すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のヒトパピローマウイルスワクチン市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.ヒトパピローマウイルスワクチンの世界市場規模および予測は？

2.予測期間中、世界のヒトパピローマウイルスワクチン市場を形成するCOVID-19の阻害要因と影響は？

3.ヒトパピローマウイルスワクチンの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.ヒトパピローマウイルスワクチンの世界市場における競争戦略は？

5.ヒトパピローマウイルスワクチンの世界市場における技術動向と規制の枠組みは？

6.ヒトパピローマウイルスワクチンの世界市場における主要ベンダーの市場シェアは？

7.ヒトパピローマウイルスワクチンの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • がん治療におけるヒトパピローマウイルスワクチン関連用途
      • 画期的な製薬技術革新として広く賞賛される
      • がんの研究開発に対する政府の資金提供
    • 抑制要因
      • インフラストラクチャの不十分な提供
    • 機会
      • 世界の保健コミュニティの間でHPVイントロダクションへの支持が拡大
      • HPVワクチンの製造プロセスの進歩
    • 課題
      • HPVの診断と治療に関する意識を高めるための地域社会の関与の欠如
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ
    • 臨床試験と動向
    • 価格分析とトレンド

第6章 ヒトパピローマウイルスワクチン市場：疾患適応症別

  • 肛門がん
  • 子宮頸がん
  • 性器いぼ
  • 中咽頭がん
  • 陰茎がん
  • 膣がん
  • 外陰がん

第7章 ヒトパピローマウイルスワクチン市場：タイプ別

  • 二価
  • 四価と九価

第8章 ヒトパピローマウイルスワクチン市場：流通チャネル別

  • 政府機関
  • 医師
  • 官民アライアンス
  • 卸売業者

第9章 南北アメリカのヒトパピローマウイルスワクチン市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のヒトパピローマウイルスワクチン市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのヒトパピローマウイルスワクチン市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
  • FIGURE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. HUMAN PAPILLOMAVIRUS VACCINE MARKET DYNAMICS
  • FIGURE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TETRAVALENT & NONAVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC & PRIVATE ALLIANCES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 148. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 149. HUMAN PAPILLOMAVIRUS VACCINE MARKET LICENSE & PRICING
目次
Product Code: MRR-436B79517C78

The Global Human Papillomavirus Vaccine Market is forecasted to grow significantly, with a projected USD 4,305.09 million in 2023 at a CAGR of 7.01% and expected to reach a staggering USD 6,929.48 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Human Papillomavirus Vaccine Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Human Papillomavirus Vaccine Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Indication, market is studied across Anal Cancer, Cervical Cancer, Genital Warts, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer, and Vulvar Cancer. The Oropharyngeal Cancer is projected to witness significant market share during forecast period.

Based on Type, market is studied across Bivalent and Tetravalent & Nonavalent. The Bivalent is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Government Entities, Physicians, Public & Private Alliances, and Wholesalers. The Government Entities is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Human Papillomavirus Vaccine Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Human Papillomavirus Vaccine Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Human Papillomavirus Vaccine Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Human Papillomavirus Vaccine Market?

4. What is the competitive strategic window for opportunities in the Global Human Papillomavirus Vaccine Market?

5. What are the technology trends and regulatory frameworks in the Global Human Papillomavirus Vaccine Market?

6. What is the market share of the leading vendors in the Global Human Papillomavirus Vaccine Market?

7. What modes and strategic moves are considered suitable for entering the Global Human Papillomavirus Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Human Papillomavirus Vaccine Market, by Disease Indication, 2022 vs 2030
  • 4.3. Human Papillomavirus Vaccine Market, by Type, 2022 vs 2030
  • 4.4. Human Papillomavirus Vaccine Market, by Distribution Channel, 2022 vs 2030
  • 4.5. Human Papillomavirus Vaccine Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Human papillomavirus vaccines associated uses for treatment of cancer
      • 5.1.1.2. Widely commended as a sweeping pharmaceutical innovation
      • 5.1.1.3. Funding by the government for R&D of cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Inadequate delivery of infrastructure
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing support for HPV introduction among the global health community
      • 5.1.3.2. Advancements in manufacturing process of HPV vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of community engagement to generate awareness regarding diagnosis and treatment of HPV
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization
    • 5.9.1. Clinical Trials & Trends
    • 5.9.2. Pricing Analysis & Trend

6. Human Papillomavirus Vaccine Market, by Disease Indication

  • 6.1. Introduction
  • 6.2. Anal Cancer
  • 6.3. Cervical Cancer
  • 6.4. Genital Warts
  • 6.5. Oropharyngeal Cancer
  • 6.6. Penile Cancer
  • 6.7. Vaginal Cancer
  • 6.8. Vulvar Cancer

7. Human Papillomavirus Vaccine Market, by Type

  • 7.1. Introduction
  • 7.2. Bivalent
  • 7.3. Tetravalent & Nonavalent

8. Human Papillomavirus Vaccine Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Government Entities
  • 8.3. Physicians
  • 8.4. Public & Private Alliances
  • 8.5. Wholesalers

9. Americas Human Papillomavirus Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Papillomavirus Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Papillomavirus Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing